A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma

Genes Chromosomes and Cancer

Volumn 54, Issue 2, 2015, Pages 91-98

  Boyle, Eileen M ^a,b   Proszek, Paula Z ^a   Kaiser, Martin F ^a   Begum, Dil ^a   Dahir, Nasrin ^a   Savola, Suvi ^c   Wardell, Christopher P ^a   Leleu, Xavier ^b   Ross, Fiona M ^d   Chiecchio, Laura ^d   Cook, Gordon ^e   Drayson, Mark T ^e   Owen, Richard G ^e   Ashcroft, John M ^f   Jackson, Graham H ^g   Anthony Child, James ^e   Davies, Faith E ^a   Walker, Brian A ^a   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c MRC HOLLAND   (Netherlands)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f MID YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISOLONE; THALIDOMIDE; VINCRISTINE; TUMOR MARKER;

ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CDKN2C GENE; CKS1B GENE; CONTROLLED STUDY; FAF1 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MULTIPLEX POLYMERASE CHAIN REACTION; RB1 GENE; TUMOR SUPPRESSOR GENE; WWOX GENE; ADULT; AGED; EARLY CANCER DIAGNOSIS; EVALUATION STUDY; FEMALE; GENETICS; MALE; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIPLEX POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS;

EID: 84916942258     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22222     Document Type: Article

References (22)

1. Alpar D, de Jong D, Holczer-Nagy Z, Kajtar B, Savola S, Jakso P, David M, Kosztolanyi S, Kereskai L, Pajor L, Szuhai K. 2013. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma. Genes Chromosomes Cancer 52:785-793.
2. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Jr., Kuehl WM, Staudt LM. 2007. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12:115-130.
3. Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, Stoppa A-M, Voillat L, Wetterwald M, Pegourie B, Voog E, Tiab M, Banos A, Jaubert J, Bouscary D, Macro M, Kolb B, Traulle C, Mathiot C, Magrangeas F, Minvielle S, Facon T, Moreau P. 2012. Long-term analysis of the IFM 99 trials for myeloma: Cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 30:1949-1952.
4. Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M, Royer B, Dib M, Voillat L, Bouscary D, Caillot D, Wetterwald M, Pegourie B, Lepeu G, Corront B, Karlin L, Stoppa A-M, Fuzibet J-G, Delbrel X, Guilhot F, Kolb B, Decaux O, Lamy T, Garderet L, Allangba O, Lifermann F, Anglaret B, Moreau P, Harousseau J-L, Facon T. 2013. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: The intergroupe francophone du myélome experience. J Clin Oncol 31:2806-2809.
5. Bergsagel PL, Kuehl WM. 2005. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23:6333-6338.
6. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ, NCRI Haematology Oncology Studies Group. 2012. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: Analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26:349-355.
7. ClinicalTrials.gov, n.d. ClinicalTrials.gov [WWW.Document]. Available at: http://www.clinicaltrial.gov/. Accessed on January 24, 2014.
8. Coll-Mulet L, Santidrián AF, Cosialls AM, Iglesias-Serret D, de Frias M, Grau J, Menoyo A, González-Barca E, Pons G, Domingo A, Gil J. 2008. Multiplex ligation-dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia. Br J Haematol 142:793-801.
9. Donahue AC, Abdool AK, Gaur R, Wohlgemuth JG, Yeh C-H. 2011. Multiplex ligation-dependent probe amplification for detection of chromosomal abnormalities in myelodysplastic syndrome and acute myeloid leukemia. Leuk Res 35:1477-1483.
10. Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, Karlin L, Hulin C, Gentil C, Guilhot F, Garderet L, Lamy T, Brechignac S, Pegourie B, Jaubert J, Dib M, Stoppa A-M, Sebban C, Fohrer C, Fontan J, Fruchart C, Macro M, Orsini-Piocelle F, Lepeu G, Sohn C, Corre J, Facon T, Moreau P, Attal M, Avet-Loiseau H. 2014. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: The IFM experience on 1195 patients. Leukemia 28:675-679.
11. Avet-Loiseau H, Florence M, Moreau Attal, Facon T, Anderson K, Harousseau JL, Munshi N, Minvielle S. 2011. Molecular heterogeneity of multiple myeloma: Pathogenesis, prognosis, and therapeutic implications. J Clin Oncol 29:1893-1897.
12. Kaiser MF, Walker BA, Hockley SL, Begum DB, Wardell CP, Gonzalez D, Ross FM, Davies FE, Morgan GJ. 2013. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. Leukemia 27:1754-1757.
13. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. 1992. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818-821.
14. Kyle RA, Rajkumar SV. 2008. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23:3-9.
15. Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Studies Group. 2012. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: The Medical Research Council Myeloma IX Trial. Blood 119:5374-5383.
16. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui C-H, Relling MV, Evans WE, Shurtleff SA, Downing JR. 2007. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-764.
17. Ross FM, Avet-Loiseau H, Ameye G, Gutiérrez NC, Liebisch P, O'Connor S, Dalva K, Fabris S, Testi AM, Jarosova M, Hodkinson C, Collin A, Kerndrup G, Kuglik P, Ladon D, Bernasconi P, Maes B, Zemanova Z, Michalova K, Michau L, Neben K, Hermansen NEU, Rack K, Rocci A, Protheroe R, Chiecchio L, Poirel HA, Sonneveld P, Nyegaard M, Johnsen HE, European Myeloma Network. 2012. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 97:1272-1277.
18. Sawyer JR, Tian E, Heuck CJ, Epstein J, Johann DJ, Swanson CM, Lukacs JL, Johnson M, Binz R, Boast A, Sammartino G, Usmani S, Zangari M, Waheed S, van Rhee F, Barlogie B. 2014. Jumping translocations of 1q12 in multiple myeloma: A novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood 123:2504-2512.
19. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. 2002. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57.
20. Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP, Harrison CJ. 2010. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 49:1104-1113.
21. Véronèse L, Tournilhac O, Combes P, Prie N, Pierre-Eymard E, Guièze R, Veyrat-Masson R, Bay J-O, Vago P, Tchirkov A. 2013. Contribution of MLPA to routine diagnostic testing of recurrent genomic aberrations in chronic lymphocytic leukemia. Cancer Genet 206:19-25.
22. Walker BA., Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, Johnson DC, Gonzalez D, Dagrada GP, Protheroe RK, et al. 2010. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116:e56-65.